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Abstract When expressed in Xenopus oocytes, GLUT1, 2 and
4 transport glucosamine with Vmax values that are three- to
four-fold lower than for glucose. The Kms for glucosamine
and glucose of GLUT1 and GLUT4 were similar. In contrast,
GLUT2 had a much higher apparent a⁄nity for glucosamine
than for glucose (Km = 0.8) 0.1 mM vs.V17^20 mM). Glucos-
amine transport by GLUT2 was con¢rmed in mammalian cells
and, using hepatocytes from control or GLUT2-null mice,
HgCl2-inhibitable glucosamine uptake by liver was shown to
be exclusively through GLUT2. These data have implications
for glucosamine e¡ects on impaired glucose metabolism and for
structure^function studies of transporter sugar binding
sites. 3 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Glucosamine (GlcN) can be produced by the hexosamine
biosynthesis pathway and converted to uridine diphosphate-
N-acetyl glucosamines. This activated sugar is used for
O-linked glycosylation of several proteins, including transcrip-
tion factors, RNA polymerase and nuclear pore proteins,
leading to alteration in their biological activity [1^3]. In-
creased activity of the hexosamine pathway represents an im-
portant mechanism by which hyperglycemia causes insulin re-
sistance [4^6]. This has been demonstrated, in particular, by
overexpressing the rate-limiting enzyme of the hexosamine
pathway, glutamine fructose-6-phosphate amidotransferase
(GFAT), which catalyzes the conversion of fructose-6-phos-
phate to N-acetylglucosamine-6-phosphate, in di¡erent tis-
sues. Transgenic overexpression of GFAT in muscles and adi-
pose tissue leads to decreased glucose uptake, mostly because
of a defect in the translocation to the plasma membrane of the
glucose transporter GLUT4 [5,7]. When GFAT is overex-
pressed in mouse pancreatic L cells it induces hyperinsuline-
mia, peripheral insulin resistance and a reduction in insulin
mRNA expression [8].
GlcN taken up by cells is phosphorylated into GlcN-6-
phosphate by hexokinase, which then bypasses GFAT to en-
ter the hexosamine pathway. Exposure of isolated adipocytes
[7] or rat skeletal muscles [9] to GlcN leads to insulin resis-
tance. In L cells, GlcN induces several dysfunctions by a
mechanism which appears to involve oxidative stress rather
than O-linked glycosylation [10]. Incubation of kidney cells
with GlcN produces a transcriptional upregulation of trans-
forming growth factor L, suggesting a possible involvement of
the hexosamine pathway in diabetic nephropathy [11]. GlcN
also induced platelet-derived growth factor-activated DNA
synthesis in rat aortic smooth muscle cells, suggesting that it
may be involved in the development of atherosclerosis [12]. In
vivo studies showed that GlcN infusion also produces insulin
resistance in both muscle and fat tissues in mice and rats
[13^15]. In humans, it has been observed that acutely admin-
istered GlcN induces a mild dysfunction in pancreatic L cell
secretion and, at higher doses, an impairment in glucose uti-
lization under hyperglycemic/hyperinsulinemic conditions [16].
GlcN is important in the metabolism of all glycoproteins,
including those in the cartilage, where it is required for the
formation of the glycosaminoglycans. In association with col-
lagen ¢bers, these molecules are responsible for the resilience
of the cartilage to deformation [17]. Destruction of joint car-
tilage occurs in osteoarthritis, and several studies have shown
that GlcN ingestion is bene¢cial for this disease [18^21]. This
compound may exert its positive e¡ects by increasing the pro-
duction of aggrecan by chondrocytes [22].
Exogenous supplementation of GlcN can thus mediate pos-
itive e¡ects on osteoarthritis but adverse e¡ects on glucose
homeostasis. Several studies have used GlcN infusion to stim-
ulate the hexosamine pathway. Here we show that three mem-
bers of the GLUT family (GLUT1, 2, 4) can transport GlcN.
However, whereas GLUT1 and GLUT4 have similar appar-
ent a⁄nities for glucose and GlcN, GLUT2 has a V20-fold
higher a⁄nity for GlcN than for glucose.
2. Materials and methods
2.1. Microinjection and GlcN uptake
GLUT1 and GLUT4 (LL489/490AA mutant) cDNAs in the pXOV
plasmid (provided by Dr. Mike Mueckler) and GLUT2 in the PSD5
plasmid were used for preparation of synthetic RNAs by in vitro
transcription, as described [23]. Transport measurements were per-
formed 3 days after RNA injection with groups of 8^12 oocytes.
Uptake was initiated by incubating oocytes in 200 Wl of MBS (NaCl
85 mM, KCl 1 mM, NaHCO3 2.4 mM, MgSO4 1 mM, Ca(NO3)2 0.33
mM, CaCl2 0.55 mM, HEPES 4 mM) containing 10 WCi of D-[1-
3H]GlcN or D-[1-3H]glucose (NEN Life Science) diluted in non-radio-
active GlcN or glucose, respectively, at ¢nal concentrations ranging
from 100 WM to 100 mM. Uptake was terminated after 15 min by
washing the oocytes with ice-cold MBS containing HgCl2. Individual
oocytes were then dissolved individually in 5% sodium dodecylsulfate
(SDS) and counted. Curves corresponding to the Michaelis^Menten
equation were ¢tted to the data and transformed to Eadie^Hofstee
plots for Km and Vmax determination.
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2.2. Transfection of HEK293T cells and measurement of
2-deoxyglucose and GlcN transport
HEK293T cells were transfected with pcDNA3 (Invitrogen) vector
containing the full-length GLUT2 cDNA as described [24]. Transport
was measured as HgCl2-inhibited 2-deoxyglucose (2-DOG) or GlcN
uptake. Brie£y, 105 GLUT2-expressing cells were incubated with 5 WCi
of either [1,2-3H]deoxy-D-glucose or D-[1-3H]GlcN (NEN Life Science)
diluted in cold 2-DOG or cold GlcN at ¢nal concentrations of 2 mM
and 0.5 mM, respectively, for 3 min in the presence or absence of
1 mM HgCl2. Cells were then washed with cold PBS containing 1 mM
HgCl2, lysed in 5% SDS, and counted. For normalization, the protein
concentration of the cell lysate was determined by BCA assay (Pierce).
2.3. Animals
RIPGLUT1UGLUT23=3 mice were obtained as described previ-
ously and were from our own colony [25]. C57Bl/6J mice used as
control were purchased from BRL (Switzerland).
2.4. Hepatocyte preparations
Livers from 8-week-old mice were perfused through the inferior
vena cava with a bu¡er consisting of 140 mM NaCl, 2.6 mM KCl,
0.28 mM Na2HPO4, 5 mM glucose and 10 mM HEPES (pH7.4). The
perfusion was ¢rst for 5 min with the bu¡er supplemented with
0.1 mM EGTA and then for 15 min with the bu¡er containing
5 mM CaCl2 and 0.2 mg/ml collagenase type 2 (Worthington). All
the solutions were prewarmed to 37‡C and gassed with a mixture of
95% O2/5% CO2, resulting in a pH of 7.4. The isolated hepatocytes
were ¢ltered with nylon mesh (0.75 mm in diameter), washed twice
with the perfusion bu¡er without collagenase, resuspended in a small
volume of Dulbecco’s modi¢ed Eagle’s medium (DMEM; Gibco) and
counted. The viability of hepatocytes was measured by trypan blue
staining. The samples with viability less than 90% were discarded.
2.5. GlcN uptake study in hepatocyte
Hepatocytes were preincubated for 2 h at 37‡C in DMEM in the
absence of glucose but with pyruvate 1 mM and lactate 10 mM, then
washed once with Krebs^Ringer bu¡er containing 10 mM HEPES,
pH 7.4, and 1% bovine serum albumin (BSA). Uptake was initiated
by diluting 20 Wl of the cell suspension (25U106 cells/ml) with 230 Wl
of GlcN at concentrations of 500 WM and containing 1.25^5 WCi
D-[1-3H]GlcN per assay (1 Ci = 37 GBq). Uptake was stopped after
2 min with 1.5 ml of ice-cold PBS (10 mM Na2HPO4W2H2O/138 mM
NaCl/2.7 mM KCl/1.76 mM KH2PO4, pH 7.4) containing 1 mM
HgCl2 (stop solution). After two washings in stop solution, the cells
were lysed in 0.1% SDS, an aliquot was kept for protein determina-
tion (as above), and the rest was used for determination of radio-
activity by L-counter.
3. Results
3.1. GlcN transport by GLUT1, 2 and 4 expressed in
Xenopus oocytes
GLUT1, GLUT2 and GLUT4 synthetic mRNAs were in-
jected in Xenopus oocytes. Glucose and GlcN uptake assays
were performed 3 days later. The apparent a⁄nity of the
di¡erent GLUTs for GlcN was measured in uptake experi-
ments performed in the presence of di¡erent concentrations
of the substrate. Preliminary studies showed that uptake was
linear for 45 min in the presence of 20 mM substrate. We
therefore determined the uptake rates using 15 min incubation
periods. Similar experiments were performed for measuring
glucose uptake a⁄nities. Fig. 1 shows the Michaelis^Menten
kinetics for GlcN and glucose uptake by GLUT1, GLUT2
and GLUT4 as well as the Eadie^Hofstee transformations
of these data. GlcN uptake by GLUT1 was with a Km of
2.1S 0.5 mM, close to the Km of V3 mM for glucose. Vmax
was of 4270S 410 pmol/oocyte/h for GlcN, approximately
4.3-fold lower than for glucose (18 400 pmol/oocyte/h). For
GLUT2, the Km for GlcN was surprisingly low, 0.8 S 0.1
mM, or 21-fold lower than the Km for glucose (V17 mM),
indicating a much higher apparent a⁄nity for GlcN than for
glucose. Vmax for GlcN was 3610S 520 pmol/oocytes/h,
Vthree-fold lower than for glucose (12 000 pmol/oocyte/h).
For GLUT4, the Km for GlcN was 3.9 S 0.3 mM, as com-
pared to a Km of V6.6 mM for glucose. The Vmax value for
GlcN was 2130S 330 pmol/oocyte/h, 3.2-fold lower than for
glucose (V6800 pmol/oocyte/h).
3.2. GlcN transport in GLUT2-transfected 293T cells
In order to check the ability of GLUT2 to transport GlcN
in mammalian cells, we performed GlcN and 2-DOG uptake
experiments in cells transiently transfected with GLUT2 or a
control plasmid. Fig. 2 shows that speci¢c 2-DOG uptake was
increased 2.6-fold in GLUT2-expressing cells (1064S 94 pmol/
6
Fig. 1. GlcN transport by GLUT1, 2 and 4 expressed in Xenopus oocytes. GLUT1, 2 and 4 were expressed from synthetic RNAs in Xenopus
oocytes and their transport properties for GlcN and glucose evaluated. Top panel: Concentration dependence of GlcN (open circle, plain line)
and glucose (¢lled triangles, dashed line) uptake by oocytes injected with GLUT1. Left: Data were ¢tted to the Michaelis^Menten equation.
Each value is the meanSS.D. of at least eight oocytes. Right: Eadie^Hofstee transformation of the uptake data. As determined in three sepa-
rate experiments, Km for GlcN was 2.1S 0.5 mM (Vmax : 4270S 410 pmol/oocyte/h). For glucose, the data were obtained from one experiment
(Km : V3 mM, Vmax : 18 400 pmol/oocyte/h) and were in agreement with Km described in the literature. Middle panel: GlcN and glucose uptake
experiments performed as described above but for GLUT2-injected oocytes. Left: Michaelis^Menten ¢t of the uptake data. Each value is the
meanSS.D. of at least eight oocytes. Right: Eadie^Hofstee transformation of the uptake data. Km value was 0.8 S 0.1 mM for GlcN (Vmax :
3610S520 pmol/oocyte/h) and 17 mM for glucose (Vmax : 12 000 pmol/oocyte/h). Lower panel: GlcN and glucose uptake experiments performed
as described above but for GLUT4-injected oocytes. Left: Michaelis^Menten ¢t of the uptake data. Each value is the meanSS.D. of at least
eight oocytes. Right: Eadie^Hofstee transformation of the uptake data. Km value was 3.9 S 0.3 mM for GlcN (Vmax : 2130 pmol/oocyte/h) and
6.6 mM for glucose (Vmax : 6800 pmol/oocyte/h).
Fig. 2. GlcN and 2-DOG transport in GLUT2-transfected
HEK293T cells. Uptake measurements were done in cells transiently
transfected with GLUT2 or with a control (Ctr) plasmid, in the ab-
sence (blank bars) or presence (¢lled) of 1 mM HgCl2. All data are
the meanSS.D. of three di¡erent measurements. GLUT2 expression
leads to signi¢cantly increased glucose and GlcN uptake.
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min/105 cells vs. 402S 96 pmol/min/105 cells for GLUT2- and
control-transfected cells, respectively). GlcN uptake was
tested in similarly transfected cells and was 513S 13 pmol/
min/105 cells for GLUT2-transfected cells as compared to
73S 28 pmol/min/105 cells for control cells. GLUT2 is thus
also able to transport GlcN when expressed in mammalian
cells.
3.3. GlcN uptake by control and GLUT23=3 hepatocytes
In order to evaluate whether GlcN is transported by
GLUT2 in liver, we performed uptake experiments on hepa-
tocytes isolated freshly from control or GLUT2-null mice [25].
As shown in Fig. 3, HgCl2-inhibitable GlcN uptake was ob-
served only in GLUT2-expressing but not in GLUT2-null he-
patocytes.
4. Discussion
GlcN infusion has been widely used to activate the hexos-
amine pathway and GlcN administration has been shown to
be bene¢cial for osteoarthritis. However, the mechanism by
which GlcN is taken up by cells has not yet been character-
ized.
Here we show that GLUT1, GLUT2 and GLUT4 can
transport GlcN. Furthermore, we show that GLUT2 has a
very high apparent a⁄nity for this substrate. The Vmax for
transport, however, were approximately three- to four-fold
lower for GlcN than for glucose for all three transporters.
We also demonstrated that GLUT2 transports GlcN when
expressed in mammalian cells and that, in hepatocytes, the
GlcN transport activity is exclusively accounted for by
GLUT2. These data are in agreement with the fact that
GLUT2 can transport NBD-GlcN (a £uorescent analogue
of GlcN) when expressed in B lymphocytes [26].
GlcN concentration in the blood in basal condition is 60^
80 WM [27], which is between 10- (GLUT2) and 40- (GLUT4)
fold below the Km for GlcN. However, in experimental studies
GlcN is usually infused at rates giving rise to blood concen-
trations in the millimolar range and, when given orally to
patients su¡ering from osteoarthritis, its blood concentration
can reach 0.4 mM [21,28,29]. Exogenous GlcN administration
activates the hexosamine pathway, which leads to insulin re-
sistance and also to defects in insulin secretion. Whether these
e¡ects could also be due, to some extent, to competition be-
tween glucose and GlcN for uptake by the transporters is not
known. However, if this were the case, this could be more
pronounced in GLUT2-expressing cells because of this trans-
porter’s high a⁄nity for GlcN.
Structurally, GlcN di¡ers from glucose by an amino group
replacing the hydroxyl group on carbon two (C2), which ren-
ders the molecule more hydrophobic. This decreases the Vmax
for GlcN as compared to that for glucose in a similar manner
for the three GLUTs tested. The e¡ect on substrate a⁄nities
were di¡erent, however, with GLUT2 exhibiting a markedly
higher a⁄nity for GlcN as compared to D-glucose. This di¡er-
ential e¡ect on a⁄nity, however, was lower for GLUT1 and
GLUT4. GLUT2 has a Km for 2-DOG, which lacks the hy-
droxyl group in position C2, of 11 mM [30], approximately
1.6-fold lower than for glucose. Therefore, it appears that, for
GLUT2, a local hydrophobic environment at the C2 position
of the sugar leads to increased a⁄nity. This could be ex-
plained by better hydrophobic interaction between speci¢c
amino acids of the pore and C2 or to the ability of the amino
group to form hydrogen bonds. A recent model [31] proposed
that the hydroxyl group of carbon C2 of D-glucose interacts
by hydrogen bond with asparagine 317 of GLUT1, which
corresponds to asparagine 347 of GLUT2. The residue next
to this asparagine is threonine 318 for GLUT1 and methio-
nine 348 for GLUT2, a residue which is more hydrophobic
and capable of forming a hydrogen bond. However, this res-
idue may be located too far from the pore to interact with
transported substrates [31].
The QLS motif (residues 279^281 for mouse GLUT1) has
been shown to be critical for high a⁄nity substrate recogni-
tion [32]. This motif is conserved for GLUT1, 3 and 4 but not
for GLUT2, for which it is replaced by the residues HVA.
These residues could also be involved in the highly di¡erent
a⁄nities of GLUT2 for glucose and GlcN.
Additional studies using di¡erent mutants of the GLUT
isoforms will be required to better understand which amino
acids are important for recognition of GlcN. It therefore rep-
resents a new tool for investigating the motifs implicated in
substrate recognition and a⁄nity and, more precisely, which
amino acids interact with carbon C2 of glucose and its deriv-
atives.
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